Abstract:Antibiotic-resistant bacteria represent a serious threat to modern medicine and human life. Only a minority of antibacterial agents are active against Gram-negative bacteria. Hence, the development of novel antimicrobial agents will always be a vital need. In an effort to discover new therapeutics against Gram-negative bacteria, we previously reported a structure-activity-relationship (SAR) study on 1,2-disubstituted benzimidazole derivatives. Compound III showed a potent activity against tolC-mutant Escherichia coli with an MIC value of 2 μg/mL, representing a promising lead for further optimization. Building upon this study, herein, 49 novel benzimidazole compounds were synthesized to investigate their antibacterial activity against Gram-negative bacteria. Our design focused on three main goals, to address the low permeability of our compounds and improve their cellular accumulation, to expand the SAR study to the unexplored ring C, and to optimize the lead compound (III) by modification of the methanesulfonamide moiety. Compounds (25a-d, 25f-h, 25k, 25l, 25p, 25r, 25s, and 26b) exhibited potent activity against tolC-mutant E. coli with MIC values ranging from 0.125 to 4 μg/mL, with compound 25d displaying the highest potency among the tested compounds with an MIC value of 0.125 μg/mL. As its predecessor, III, compound 25d exhibited an excellent safety profile without any significant cytotoxicity to mammalian cells. Time-kill kinetics assay indicated that 25d exhibited a bacteriostatic activity and significantly reduced E. coli JW55031 burden as compared to DMSO. Additionally, combination of 25d with colistin partially restored its antibacterial activity against Gram-negative bacterial strains (MIC values ranging from 4 to 16 μg/mL against E. coli BW25113, K. pneumoniae, A. baumannii, and P. aeruginosa). Furthermore, formulation of III and 25d as lipidic nanoparticles (nanocapsules) resulted in moderate enhancement of their antibacterial activity against Gram-negative bacterial strains (A. Baumannii, N. gonorrhoeae) and compound 25d demonstrated superior activity to the lead compound III. These findings establish compound 25d as a promising candidate for treatment of Gram-negative bacterial infections and emphasize the potential of nano-formulations in overcoming poor cellular accumulation in Gram-negative bacteria where further optimization and investigation are warranted to improve the potency and broaden the spectrum of our compounds.

Synthesis, Molecular Modeling and Biological Evaluation of PSB As Targeted Antibiotics.

Synthesis, Antibacterial Activities and Molecular Docking Studies of Peptide and Schiff Bases As Targeted Antibiotics

Design, Synthesis and Antibacterial Activity Studies of Thiazole Derivatives As Potent Eckas III Inhibitors.

Design and Synthesis of Potent Inhibitors of Beta-Ketoacyl-acyl Carrier Protein Synthase III (fabh) As Potential Antibacterial Agents.

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment

Investigating the Antibacterial Potential of Novel N-Boc Isatin Schiff Bases: Combining Synthesis with In-vitro and In-silico Studies

Synthesis, molecular modeling and biological evaluation of β-ketoacyl-acyl carrier protein synthase III (FabH) as novel antibacterial agents

SAR investigation and optimization of benzimidazole-based derivatives as antimicrobial agents against Gram-negative bacteria

Design, Synthesis and Antibacterial Activities of 5-(Pyrazin-2-yl)-4h-1,2,4-triazole-3-thiol Derivatives Containing Schiff Base Formation As FabH Inhibitory.

Integrated computer-aided drug design and biophysical simulation approaches to determine natural anti-bacterial compounds for Acinetobacter baumannii

Design and Synthesis of 2-Hydroxyl-4-methoxyl-3-(3-methylbut-2-en-1-yl)-6-(4-phenylbenzoylamino)benzoic Acid Derivatives As Antibacterial Agents Based on Cajaninstilbene Acid Scaffold Hopping.

Synthesis, Antimicrobial Evaluation and Docking Study of Novel 3,5-Disubstituted-2-Isoxazoline and 1,3,5-Trisubstituted-2-Pyrazoline Derivatives

Study of Schiff-Base-Derived with Dioxygenated Rings and Nitrogen Heterocycle As Potential Β-Ketoacyl-acyl Carrier Protein Synthase III (fabh) Inhibitors.

Synthesis, Antibacterial Activities and Molecular Docking Studies of Schiff Bases Derived from N-(2/4-Benzaldehyde-Amino)Phenyl-N '-Phenyl-thiourea

Synthesis, Molecular Docking and Biological Evaluation of Metronidazole Derivatives Containing Piperazine Skeleton As Potential Antibacterial Agents

Design, synthesis and biological evaluation of amphiphilic benzopyran derivatives as potent antibacterial agents against multidrug-resistant bacteria

Synthesis, Antimicrobial Evaluation, Molecular Docking and Dynamics Simulations of Novel 2,3‐Disubstituted Quinazolin‐4(3H)‐one Derivatives

Design, Synthesis and Biological Evaluation of Novel Thiazole Derivatives As Potent FabH Inhibitors

Design, synthesis, biological evaluation and in silico studies of certain aryl sulfonyl hydrazones conjugated with 1,3-diaryl pyrazoles as potent metallo-β-lactamase inhibitors

Synthetic Optimization and Antibacterial Activity of Novel Benzodioxepine-Biphenyl Amide Derivatives